Drugs / NR1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04631406 | Jan 2021 → Aug 2025 overdue | ischemic stroke | Gary Steinberg, MD, PhD | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NR1 | “NR1 is a human embryonic stem cell (hESC) derived product for the treatment of chronic ischemic subcortical stroke” NCT04631406 ↗ |
| Modality | Cell therapy | “NR1 is a human embryonic stem cell (hESC) derived product” NCT04631406 ↗ |
| Route | Other | “NR1 administered intracerebrally” NCT04631406 ↗ |